Biocon CMD Kiran Mazumdar-Shaw tells ET Now in an interview that the Company remains extremely confident of delivering very strong numbers in its Biologics business this fiscal, with a more robust performance in the second half of the year on the back of the commercialization of biosimilar Trastuzumab in the U.S. market.
She also talks about how the recently announced Mylan-Upjohn merger announcement augurs well for Biocon’s biosimilars business in China, given that Upjohn has a very strong presence in that country.
For more on Kiran Mazumdar-Shaw’s views on Biocon’s performance overall and Biologics in particular, click to listen to the #podcast
Audio Credit: ET Now
